DocMorris AG Sees Revenue Surge but Struggles with Profitability in H1 2025
DocMorris AG reported mixed financial results for the first half of 2025, with significant revenue growth in its prescription segment, but continued financial losses and a negative price-to-earnings ratio.
2 minutes to read